Pegaptanib sodium for ocular vascular disease

Shukla, Dhananjay; Namperumalsamy, Perumalsamy; Goldbau, Mauro; Cunningham Jr., Emmett T.
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p427
Academic Journal
No abstract available.


Related Articles

  • Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. Foy, Jeffrey W.-D.; Rittenhouse, Kay; Modi, Marlene; Patel, Manju // Journal of Ocular Pharmacology & Therapeutics;Oct2007, Vol. 23 Issue 5, p452 

    Purpose: To evaluate the local tolerance, systemic toxicity, and toxicokinetics in dogs and rabbits of pegaptanib sodium, an aptamer that targets vascular endothelial growth factor (VEGF(165)).Methods: Dogs received biweekly, bilateral, intravitreous (IVT) injections of...

  • Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Ng, Eugene W. M.; Shima, David T.; Calias, Perry; Cunningham Jr., Emmett T.; Guyer, David R.; Adamis, Anthony P.; Cunningham, Emmett T Jr // Nature Reviews Drug Discovery;Feb2006, Vol. 5 Issue 2, p123 

    Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer) is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165, the VEGF isoform primarily responsible for...

  • Pegaptanib Sodium in the Treatment of Neovascular Age-Related Macular Degeneration. Querques, Giuseppe // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p225 

    Pegaptanib sodium is a polyethylene-glycolated, 28-nucleotide RNA aptamer that binds selectively to vascular endothelial growth factor (VEGF)165 but not smaller isoforms. Preclinical studies identified VEGF165 as an especially potent promoter of ocular neovascularization and inflammation....

  • Mixed results seen with anti-VEGF therapy for children's retinal diseases. Trese, Michael T. // Ophthalmology Times;5/1/2007, Vol. 32 Issue 9, p60 

    The article highlights the result of an anti-vascular endothelial growth factor treatment of pediatric retinal diseases. Using pegaptanib sodium, this treatment was directed at familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP). It showed mixed results, with a...

  • Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Singerman, L.J.; Masonson, H.; Patel, M.; Adamis, A.P.; Buggage, R.; Cunningham, E.; Goldbaum, M.; Katz, B.; Guyer, D. // British Journal of Ophthalmology;Dec2008, Vol. 92 Issue 12, p1606 

    Aims: To evaluate the safety of up to 3 years of pegaptanib sodium therapy in the treatment of neovascular age-related macular degeneration (NV-AMD). Methods: Two concurrent, prospective, multicentre, double-masked studies randomised subjects with all angiographic lesion compositions of NV-AMIJ...

  • An Update on Macugen Trials. Kulkarni, Kaushal; Prenner, Jonathan L. // Review of Ophthalmology;Dec2005, Vol. 12 Issue 12, Special section p6 

    The article presents information on the VEGF Inhibition Study in Ocular Neovascularization (VISION) study in its second year and on a trial of Macugen for diabetic macular edema. Macugen is used in curing exudative Age-related Macular Degeneration. It is also known as pegaptanib sodium and is...

  • Booster approach helps stabilize vision in AMD patients. Groves, Nancy; Tolentino, Michael // Ophthalmology Times;10/15/2006, Vol. 31 Issue 20, p46 

    The article reports that combination therapy using bevacizumab as a booster administered between injections of pegaptanib sodium helps stabilize vision in age-related macular degeneration patients. A clinician in Winter Haven, Florida try the combination and hypothesize that bevacizumab and...

  • Anti-vascular endothelial growth factor in age-related macular degeneration: Puzzle or a silent beginning! Natarajan, Sundaram // Indian Journal of Ophthalmology;Sep2013, Vol. 61 Issue 9, p475 

    The author reflects on the association of elevated vascular endothelial growth factor (VEGF) levels in the pathogenesis of age-related macular degeneration (Wet-AMD). The author discusses three anti-VEGFs for AMD treatment including pegaptanib sodium, ranibizumab, and bevacizumab. The author...

  • Retinal specialists share experience with anti-VEGF therapy. Guttman, Cheryl; Blinder, Kevin J.; Sharma, Mithlesh C. // Ophthalmology Times;6/1/2005, Vol. 30 Issue 11, p20 

    Assesses the efficacy of anti-vascular endothelial growth factor (VEGF) therapy in treating choroidal neovascularization associated with age-related macular degeneration. Characteristics of anti-VEGF therapy; Benefits provided by pegaptanib sodium to eye diseases therapeutics; Factors that...

  • Pegaptanib for age-related macular degeneration.  // WHO Drug Information;2005, Vol. 19 Issue 1, p32 

    The article reports that the U.S. Food and Drug Administration has approved pegaptanib sodium injection, a new therapy to slow vision loss in people with the eye disease neovascular age-related macular degeneration (AMD). Pegaptanib is a selective vascular endothelial growth factor antagonist....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics